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Ann E. Pulver,2,6 and Stephen T. Warren1,7,*
Schizophrenia (SZ) is a severe psychiatric illness that affects ~1% of the population and has a strong genetic underpinning. Recently,
genome-wide analysis of copy-number variation (CNV) has implicated rare and de novo events as important in SZ. Here, we report
a genome-wide analysis of 245 SZ cases and 490 controls, all of Ashkenazi Jewish descent. Because many studies have found an excess
burden of large, rare deletions in cases, we limited our analysis to deletions over 500 kb in size. We observed seven large, rare deletions in
cases, with 57% of these being de novo. We focused on one 836 kb de novo deletion at chromosome 3q29 that falls within a 1.3–1.6 Mb
deletion previously identified in children with intellectual disability (ID) and autism, because increasing evidence suggests an overlap of
specific rare copy-number variants (CNVs) between autism and SZ. By combining our data with prior CNV studies of SZ and analysis of
the data of the Genetic Association Information Network (GAIN), we identified six 3q29 deletions among 7545 schizophrenic subjects
and one among 39,748 controls, resulting in a statistically significant association with SZ (p ¼ 0.02) and an odds ratio estimate of 17
(95% confidence interval: 1.36–1198.4). Moreover, this 3q29 deletion region contains two linkage peaks from prior SZ family studies,
and the minimal deletion interval implicates 20 annotated genes, including PAK2 and DLG1, both paralogous to X-linked ID genes
and now strong candidates for SZ susceptibility.Introduction
Substantial evidence from both twin and family studies
has demonstrated a strong genetic component for the
development of schizophrenia (SZ [MIM 181500]), one of
the most frequent and devastating psychiatric diseases in
the world.1,2 Genome-wide association studies (GWAS)
with unprecedented sample sizes have yielded only a small
number of candidate loci with odds ratio estimates of
1.2–1.4,3–5 leaving a substantial component of the genetic
variance unexplained. This missing heritability has led to
the view that selection against common susceptibility
loci may be greater than previously believed and has
driven the search for rare and de novo variation as contrib-
utors to predisposition, which could account for both the
substantial hereditability estimates and the absence of
significant association with common genome variation.
Copy-number variation (CNV) has been the most widely
considered source of rare variation in complex disorders
such as SZ, fueled by the advent of technology that
could rapidly and reliably identify submicroscopic copy-
number variants (CNVs). Indeed, several studies have
documented rare and often de novo deletions and duplica-
tions in SZ, with significantly more such events in
cases versus controls.6–10 This increased CNV burden
contains a minority of CNV risk loci that are shared among
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The Americthat are observed only once.2 Walsh et al. reported that
SZ cases were four times more likely than controls to carry
gene-containing CNVs > 100 kb.9 The International
Schizophrenia Consortium reported a 1.67-fold excess of
deletions > 500 kb in cases.6 Need et al. found an excess
of deletions > 2 Mb in cases.7 Kirov and colleagues
reported that CNVs > 1 Mb were 2.6-fold more common
in cases, with deletions specifically being 4.53-fold more
common in cases.11 In addition, Xu et al. reported an
8-fold increase in de novo CNV in SZ trios, lending further
support to the rare-variant hypothesis for SZ suscepti-
bility.10 Despite these many reports, only a small number
of specific CNVs are found to be enriched in SZ cases,
including deletions at 1q21, 15q11, 15q13, 22q11, and
in the NRXN gene, as well as duplication at 16p11.6,8,11,12
We sought to examine the burden of large rare CNVs in
a cohort of 245 unrelated SZ cases and 490 unaffected
controls, all of whom were of Ashkenazi Jewish descent.
The Ashkenazim are an ethnically and genetically distinct
population,13,14 although their prevalence of SZ appears
similar to the general population. For ease of comparison
with other studies, we limited our analysis to deletions
larger than 500 kb. Available parents of 182 cases were
also genotyped for the assessment of inherited or de
novo status. We found a 2.8-fold excess of large rare dele-
tions in SZ cases, which is fully consistent with other
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3q29 and 22q11, are also found in other SZ populations
and show a statistically significant enrichment in SZ cases,
with a17-fold increase in risk for SZ associated with the
3q29 variant.
Subjects and Methods
Study Subjects
Ashkenazi Jewish individuals affected with SZ were recruited
nationally over a 6 yr period through advertisements in newspa-
pers and Jewish newsletters, talks to community organizations,
letters to leaders of the Jewish community, and a study website
(Johns Hopkins Epidemiology-Genetics Program in Psychiatry).
Case-parent trios were eligible for inclusion in these analyses if
the proband met DSM-IV criteria for a SZ diagnosis and all four
grandparents were of Ashkenazi Jewish descent. When available,
DNA from parents of probands was also collected. This recruit-
ment effort led to 300 eligible families for analysis. Seventy-two
percent of affected individuals in our study were male, and the
mean age of onset for SZ was 19.3 yrs (Table S1, available online).
Recruitment of this population has been previously described.15
All recruitment methods and protocols for collection of clinical
data and blood samples were approved by the Johns Hopkins insti-
tutional review board, and informed consent was obtained from
all individuals.
Probands were assessed for psychiatric illness according to estab-
lished procedure, as follows: a trained clinical examiner (doctoral-
level clinical psychologist) interviewed each study subject in
person (usually in their home) using the Diagnostic Interview
for Genetic Studies (DIGS), a standard, semistructured instrument
widely used for phenotypic classification of individuals for psychi-
atric genetic studies. These interviews were tape recorded. For each
study subject, medical records were also obtained, and collateral
interviews with at least one additional informant were conducted.
The examiner then completed a written diagnostic workup,
including relevant clinical features and course of illness. All
collected clinical information (tape-recorded interviews, DIGS
interview booklets, medical records, collateral interview informa-
tion, and written diagnostic workup) was forwarded to two inde-
pendent, trained clinicians, who reached a consensus diagnosis
of SZ before an individual was included for study. Complete details
about clinical methods are available in Fallin et al.16
Ascertainment of Controls
Control subjects were selected from two cohorts: one from a study
of Crohn disease (CD) in the Ashkenazim, and one from a study of
neuromuscular disease (Parkinson disease [PD] and dystonia) in
the Ashkenazim. The Mount Sinai and/or Beth Israel institutional
review boards approved all recruitment methods and protocols for
DNA collection, and informed consent was obtained from all indi-
viduals. Control subjects were not screened for psychiatric disease.
Population substructure analysis using noncorrelated SNPs
showed cases and controls to be a homogeneous population.
Crohn Disease Cohort
Ashkenazi Jewish individuals with CD were recruited over a 3 yr
period through New York metropolitan area physicians partici-
pating in the New York Crohn’s Study Group, which is based at
The Mount Sinai Medical Center. Patients were phenotyped by
a gastroenterologist and were included in the study if they met
the definition of CD according to the Montreal classification and
if all four grandparents were of Ashkenazi Jewish descent.230 The American Journal of Human Genetics 87, 229–236, August 1Neuromuscular Cohort
Ashkenazi Jewish individuals with PD or dystonia were recruited
from the Department of Neurology at Beth Israel Medical Center
and through research solicitation. Each study participant was con-
sented, and histories, exams, and blood samples were obtained.
Determination of Ashkenazi Jewish ancestry was based on patient
report of one or more Ashkenazi grandparents.
Genotyping and Identification of CNVs
DNA was extracted with the Gentra Puregene Kit or the QIAGEN
DNeasy Blood and Tissue Kit. All DNA used for this study was
extracted from blood (no cell-line DNA was used). Samples were
genotyped with the Affymetrix Human Genome-Wide SNP Array
6.0 at Emory University. Genotyping was performed with the
use of the Birdseed algorithm, as implemented in Affymetrix
Power Tools software. Individual genotypes with confidence
scores < 0.9 were excluded. SNPs with completion rates < 90%
were also excluded. This rendered 814,263 autosomal SNPs.
For CNV analysis, normalization and log ratio data calculation
was achieved with the use of the Affymetrix Power Tools software
(version 1.10.0). Log(2) ratio data for autosomes were extracted
and analyzed with the use of three algorithms: GLAD,17 GADA,18
andBEAST (G.A.S., unpublished data). CNVs called by only a single
algorithmwere removed fromanalysis.Whenalgorithmsdisagreed
on endpoint determination, the smallest startpoint and the largest
endpoint (i.e., the largest interval) were considered. Putative
deletion intervals were filtered by size (> 500 Kb), the number of
SNPs in the deletion interval (> 20 SNPs), and SNP homozygosity
rate (> 90%).
Samples were excluded (1) if they failed the manufacturer’s rec-
ommended cutoffs for chip quality control; (2) patterns of SNP
genotypes revealed inconsistent family structure (trios only) or
unknown duplicates or if the heterozygosity was greater than three
standard deviations (SD) above themean and themissing data rate
was > 3 SD above the mean (indicating potential sample mixing);
(3) if patterns of SNP genotypes revealed cryptic relatedness deter-
mined by pairwise identity-by-state analysis (first- and second-
degree relationshipswere removed, controlspreferentially removed
when possible); or (4) if the number of detected CNVs were> 3 SD
from the mean number of CNVs in the overall sample (Table S2).
Validation of Variants and Endpoint Mapping
The 3q29 variant was validated by TaqMan Assay (ID
Hs03476335_cn). Assays were performed in quadruplicate in
384-well format with 10 ng of DNA per reaction. Copy number
was determined with the use of CopyCaller software version 1.0
(Applied Biosystems). Fine mapping of deletion endpoints was
accomplished with the use of a custom-designed Agilent array
with 244,000 probes, of which 27,661 are located in the terminal
6.2 Mb of the long arm of chromosome 3. Patient and reference
genomes were labeled and hybridized according to the manufac-
turer’s instructions. Arrays were scanned with an Axon GenePix
4000B scanner, and data were extracted and analyzed with the
Feature Extraction and DNA Analytics programs, respectively.
The 10q21 variant was validated by long PCR across the deletion
endpoints and sequencing of the PCR product to map the precise
breakpoints. The 16p11 deletion and both 22q11 deletions were
validated by Illumina HumanOmni1-Quad array, according to
the manufacturer’s instructions. Deletions were called with the
use of cnvPartition 2.4.4 from within GenomeStudio v2009.2.
Deletions were detected with confidence scores of 2249.5 (16p11),
1730.5 (22q11), and 2891.3 (22q11).3, 2010
Table 1. Rare Deletions > 500 kb in Cases and Controls
Chromosomal Region Start Size (kb) No. of Cases No. of Controls No. of Genes Inheritance in Case
3p26.3 1302426 525 2 1 1 inherited/ unknown
3q29 197412253 836 1 0 19 de novo
10q11.23-q21.1 53181991 4266 1 0 4 inherited
16p11.2-p12.1 26581888 2980 1 0 41 de novo
22q11.21 17030967 3139 2 0 66 de novo/ de novo
3q12.3 102522271 672 0 1 11 -
5p15.2 12868768 622 0 1 0 -
9p21.1 31487560 788 0 1 0 -
10q11.21-q11.23 45576362 5912 0 1 52 -Statistical Analysis
All p values and odds ratios were calculated with Fisher’s exact test
or the Cochran-Mantel-Haenszel exact test, stratified by study, in
the R statistical package.19–21 For multiple-test correction by
permutation, one million randomized data sets were created for
all four deletions. The observed p value for each deletion was
compared to the lowest p value in the randomized set of four
p values.22 For the permutation analysis, all test statistics were
Cochran-Mantel-Haenszel chi-squared tests with continuity cor-
rection (exact tests being too computationally inefficient for
permutation analysis).Results
In our populationof 245 SZ cases and490 controls,we iden-
tified a total of 192 deletions, mapping to 22 genomic
locations (Table S3). After excluding variants that overlap-
pedR 60% of their length with a deletion reported in the
Database of Genomic Variants, 12 variants at nine loci
remained (Table 1), with seven of these variants in cases
(0.028 per person) and five in controls (0.01 per person).
This 2.8-fold excess of rare variants in cases, although
not statistically significant, nevertheless reiterates what
has been observed in many studies of CNV and SZ.6–10,23
Variants were also larger in cases (case average [median]:
2150 kb [2791 kb] versus 1629 kb [672 kb] in controls)
and contained more genes overall (132 genes at case loci
versus 64 genes in control loci), as well as more genes
per locus (18.8 genes per case locus versus 12.8 genes per
control locus). Of the seven case deletions, two were
inherited, four were de novo, and one could not be deter-
mined.
The four case-only loci (at 3q29, 10q11.23-q21.1,
16p11.2-p12.1, and 22q11) were investigated for deter-
mining whether these deletions were reported in three
previous CNV studies of SZ.6,9,10 In addition, we also
obtained and extracted intensities from the raw data of
2169 SZ cases and 2419 controls from the Genetic Associ-
ation Information Network (GAIN) study.4 We found
a statistically significant excess of deletions in cases at
3q29 and 22q11 (Figure 1 and Table 2). In total, we identi-The Americfied six deletions at the 3q29 locus in 6107 cases and none
in 6502 controls (p ¼ 0.0074, odds ratio N, 95% confi-
dence interval [CI]: 1.50–N). Whereas the 3q29 deletion
discovered in our study is 836 kb, in all other studies the
interval is a larger 1.3–1.6 Mb, completely encompassing
the 836 Kb de novo event (Figure 2). We also identified
29 22q11 deletions in 6107 cases and none in 6502
controls (p ¼ 4.7 3 1010, 95% CI: 8.19–N). This is
consistent with studies showing the 22q11 deletion to
be the single strongest known genetic influence on SZ
susceptibility.
We pursued the 3q29 locus further by examining data
from an Icelandic cohort of 1438 SZ cases and 33,246
controls.8 In this sample, a 378 kb region, completely
within the large 1.6 Mb deletion, had been interrogated
for copy number with the use of 49 SNPs. Of these, 36
SNPs fall within our smaller 836 kb deletion (Figure 2).
Among these data, only one additional deletion was found
in a control individual. In aggregate, we identified six 3q29
deletions in a total of 7545 cases, compared to one deletion
in 39,748 controls. We note that Itsara et al. had also iden-
tified three of these deletions from the literature, but
in their study this observation failed to reach statistical
significance.23 Our combined meta-analysis refines the
odds ratio estimate to 16.98 (p ¼ 0.0097, 95% CI: 1.36–
1198.4). By permutation testing we calculate a multiple-
test-adjusted p value of 0.02 (correcting for four deletions).
The frequency of the 3q29 deletion appears to be consis-
tent among populations, justifying the combining of
data across populations to generate an overall odds ratio
of 31.5 (uncorrected p ¼ 0.0001, 95% CI: 3.83–1440.6).
Even at the lowest end of this broad CI, this odds ratio
rivals that of any GWAS of SZ and suggests that the 3q29
deletion confers a significant risk for this severe psychiatric
phenotype.Discussion
A recurrent 1.6 Mb microdeletion of 3q29 mediated by
recombination between flanking segmental duplicationsan Journal of Human Genetics 87, 229–236, August 13, 2010 231
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Figure 1. Raw Data, Validation, and Fine Mapping of the Chromosome 3q29 Variant
(A) Raw log ratio data from the Affymetrix Human Genome-Wide SNP Array 6.0 is shown for chromosome 3, 190 Mb–3qtel, for the SZ
proband and both parents. The 3q29 de novo deletion is denoted with an arrow.
(B) TaqMan validation data for the 3q29 variant for the SZ proband and both parents (the father was assayed in replicate). Results of ABI
CopyCaller software are shown; predicted copy number is indicated on the y axis.
(C) Raw log ratio data for the SZ proband from a custom Agilent array with 27,661 probes in the terminal 6.2 Mb of chromsome 3q.
Position on chromosome 3 is plotted on the x axis (194.3–200.1 Mb shown), log ratio data on the y axis. The deletion region is indicated
with an arrow.has been described (MIM 609425).24–26 This 3q29microde-
letion is most often encountered in children with mild
to moderate intellectual disability (ID) that can be associ-
ated with microcephaly, dysmorphology, and autistic
features.25,26 Like other deletions, such as those found at
1q21, 15q13, and 22q11, the same CNVs can be identified
in children with ID and/or autism (MIM 209850) as well
as in adults with SZ.27–31 Indeed, Quintero-Rivera et al.
reported a 10-yr-old girl with 3q29 deletion syndrome
and a history of both SZ and autism (Quintero-Rivera and
Martinez-Agosto, 2009, Am. Soc. Hum. Genet., abstract).
Moreover, the schizophrenic individual we report here
with the 836 kb deletion has a childhood history of mild
learning disability and impaired social interaction. Our
result therefore strengthens the emerging link between
SZ and childhood autism or ID.12,32–34
The data for the 3q29 deletion are similar to what has
been observed at additional loci, including 1q21, 15q11,232 The American Journal of Human Genetics 87, 229–236, August 115q13, and 16p11, although these copy-number changes
are approximately an order of magnitude more frequent
that the 3q29 deletion, in both cases and controls.
The low frequency of the 3q29 deletion is likely why it
was not detected as a risk variant in any one study; even
within the combined meta-analysis of over 7000 cases
that we present here, only modest statistical significance
is achieved. There are no clear relationships between the
genes in the 3q29 interval and other SZ-associated inter-
vals, though detailed functional studies may reveal interac-
tions that are as yet unknown.
Additional support for the 3q29 interval comes from two
linkage studies. Bailer et al. reported linkage to 3q29 in
eight pedigrees35 (five SZ families, three bipolar disorder
families), and two follow-up studies define a linkage peak
at 197.09 Mb, within 400 kb of the de novo event we
observe at 3q29.36,37 Furthermore, Devlin et al. reported
a pedigree showing a LOD score of 2.6 with marker3, 2010
Table 2. Aggregate Data for Deletions at Four Loci, in Independent SZ CNV Studies
3q29 10q11.23 16p12.1 22q11
Study Cases Tested Controls Tested Cases Controls Cases Controls Cases Controls Cases Controls
Present study 245 490 1 0 1 0 1 0 2 0
Walsh 150 256 1 0 0 0 0 0 0 0
Xu 152 156 0 0 0 0 0 0 3 0
ISC 3391 3181 2 0 0 0 0 0 13a 0
GAIN EA 1215 1440 1 0 0 0 1b 0 10 0
GAIN AA 952 978 1 0 0 0 0 0 1 0
Subtotal 6107 6502 6 0 1 0 2 0 29 0
deCODE 1438 33246 0 1 nt nt nt nt nt nt
Total 7545 39748 6 1
OR (95% CI) 16.98 (1.36–1198.4) N (0.051–N) N (0.29–N) N (8.19–N)
p value 0.0097 0.33 0.15 4.7 3 1010
Italics indicate total deletions across samples. EA, European American; AA, African American; nt, not tested.
a Includes two ‘‘atypical’’ deletions reported by the ISC.
b Deletion is 941 kb, completely contained within the 2980 kb de novo deletion discovered in the present sample.D3S1311, which maps within our 3q29 deletion region.38
Finally, nominal association was reported in an SZ case-
control study using 23 SNPs immediately adjacent to the
distal breakpoint of the 836 kb deletion.28 These data
imply that additional variants at the 3q29 locus, such as
single-base mutations in protein-coding or regulatory
sequence, may be contributing to SZ susceptibility.
Within the 836 kb 3q29 deletion interval, there are 19
annotated genes (Table S5). Of these, p21-activated kinase
2 (PAK2) appears particularly interesting because it has a
highly similar paralog that, when mutated, causes X-linked
ID (PAK3) and is strongly expressed in the brain.25 PAK2
has been shown to attenuate the inhibitory interaction
between RhoGDI and Rac1,39 the latter being a prominent
regulator of spine morphology and plasticity that was also
recently reported to be regulated by the ‘‘schizophrenia-
related’’ protein, DISC1.40 We also note that the telomeric
breakpoint of the minimal deletion is 4.7 kb from the tran-
scriptional stop of the DLG1 gene. The DLG1 gene has
been implicated in SZ by both case-control SNP association
and protein-based assays in postmortem brain tissue.41,42
Furthermore, DLG1 (also called SAP97) has been shown to
bind to neuroligin (an autism-susceptibility gene) and the
AMPA receptor subunit GluR1.43–45 There is mounting
evidence to implicate perturbation of the glutamate system
in SZ pathology.46 Although the remaining genes in this
interval cannot be confidently excluded as being function-
ally relevant to thisdisorder, this study, alongwith the cumu-
lative prior evidence, strongly implicates PAK2 andDLG1 as
candidate genes for SZ susceptibility.
Here, we assessed CNV in SZ using a genetic isolate, the
Ashkenazi Jewish population. We hypothesized that if rare
variants contribute to risk, we might identify a risk variantThe Americthat, although rare, was shared by multiple cases in this
population. Instead, we identified mostly de novo events,
including SZ-related deletions at 16p11.2-p12.1 and
22q11. However, we did find that 3q29 deletions are
highly associated with SZ, regardless of ethnicity. This
observation provides an additional example of amicrodele-
tion conferring either childhood-onset ID or adult-onset
SZ, strengthening the emerging overlap between these
two disparate phenotypes. Our data imply that 3q29 dele-
tions may impart a genetic susceptibility to SZ that
approaches the strength of the well known 22q11 deletion.
Exploring such rare deletions may prove to be the single
most fruitful approach to begin to unravel themechanisms
of SZ, not because these deletions themselves are a frequent
cause of SZ, but rather because they illuminate genes, such
as PAK2 and DLG1 described here, that provide the
substrate for further study.Supplemental Data
Supplemental Data include five tables and one figure and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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